Muromonab CD3

Drug Profile

Muromonab CD3

Alternative Names: Anti-CD3 monoclonal antibody OKT3; Monoclonal antibody OKT3; OKT-3; OKT3 antibody; Orthoclone OKT-3

Latest Information Update: 11 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
  • Discontinued Cancer; Renal cancer

Most Recent Events

  • 14 Oct 2002 A case report has been added to the adverse events section
  • 12 Feb 1999 Launched for Renal transplant rejection in Argentina (IV-injection)
  • 31 Dec 1998 Discontinued - Clinical-Phase-Unknown for Renal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top